Figures & data
Table 1. Body system diseases and prior psychoactive and pain medications.
Figure 1. Patient disposition.
Table 2. Demographic information for all included patients, and for patients in the three initial-dose cohorts.
Figure 2. Least squares mean of patient-level monthly healthcare costs, overall and by initial-dose cohort (US dollars/month). Treatment month is reported as months prior to treatment initiation (negative values) and months following initiation (positive values). Overall, n = 10,987; High Initial-Dose Cohort, n = 1045; Standard Initial-Dose Cohort, n = 6686; Low Initial-Dose Cohort, n = 3256. US, United States.
Table 3. Type 3 tests of fixed effects from the baseline covariate adjusted longitudinal model.
Table 4. Pairwise comparisons and sensitivity analysis among initial-dose cohorts.
Table 5. Rate of cost change (US dollars/month) and sensitivity analysis prior to and following initiation of duloxetine in patients with major depressive disorder.